Nemolizumab
monoclonal antibody
Nemolizumab, sold under the brand name Nemluvio, is a humanized monoclonal antibody used for the treatment of prurigo nodularis and atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Nemolizumab is humanized IgG2 monoclonal antibody that inhibits interleukin-31 signaling by binding selectively to interleukin-31 receptor alpha. It is an interleukin-31 receptor antagonist. IL-31 is a cytokine involved in pruritus, inflammation, epidermal dysregulation and fibrosis. By inhibiting IL-31-induced responses, nemolizumab prevents the release of proinflammatory cytokines and chemokines.
Nemolizumab was approved for medical use in the United States in August 2024, and in the European Union in February 2025. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Medical uses
Nemolizumab is indicated for the treatment of adults with prurigo nodularis. In December 2024, the indication for nemolizumab was updated to include the treatment of people twelve years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
History
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.
This brief starts where responsible research should: with the source description of “Nemolizumab” as monoclonal antibody. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the general reference register because the source frames it as monoclonal antibody. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Vocabulary and entity names are the principal evidence signals here, because they determine the precision of every later search. The source revision retrieved here is dated Feb 9, 2026. The linked authority identifier is Q30314619. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024, 2025 and 2016.
The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Nemolizumab”, its source revision and the description used here.
- Expand the search: follow Nemolizumab primary sources, Nemolizumab archive and Nemolizumab research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Nemolizumab”?
- Which cited source is closest to the event, object or claim?
- What terminology or title could unlock a more precise catalogue search?
Search terms from this dossier
This entry incorporates text from “Nemolizumab” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.